^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
6222 / 24 - Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer
Published date:
03/15/2023
Excerpt:
A total of 36 patients with advanced or recurrent EGFR-mutant NSCLC were analyzed. In multivariate analysis, p53 expression in tumors was an independent predictor of PFS after ICI-based therapy (p = 0.002). In patients with common EGFR mutations, high AXL expression was a predictor of shorter PFS and overall survival after ICI-based therapy (log-rank test; p = 0.04 and p = 0.02, respectively).
